Chiu Hui-Wen, Yeh Ya-Ling, Ho Sheng-Yow, Wu Yuan-Hua, Wang Bour-Jr, Huang Wei-Jan, Ho Yuan-Soon, Wang Ying-Jan, Chen Li-Ching, Tu Shih-Hsin
Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 11031, Taiwan.
Division of Nephrology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, Taipei 11031, Taiwan.
Cancers (Basel). 2019 Nov 1;11(11):1703. doi: 10.3390/cancers11111703.
Radiation therapy (RT) is one of the main treatments for triple-negative breast cancer (TNBC). However, many patients experience RT failure due to the metastatic potential of RT and the radiation resistance of several cancers. Histone deacetylase inhibitors (HDACis) can serve as radiosensitizers. In this study, we investigated whether a novel HDACi, TMU-35435, could reinforce radiosensitivity through the induction of misfolded protein aggregation and autophagy in TNBC. Significantly enhanced toxicity was found for the combination treatment compared with TMU-35435 or irradiation (IR) treatment alone in TNBC cells. The combination treatment induced misfolded protein aggregation and TMU-35435 inhibited the interaction of HDAC6 with dynein. Furthermore, the combined treatment induced endoplasmic reticulum (ER) stress but did not trigger apoptosis. In addition, the combination treatment caused autophagic cell death. Tumor growth in the mouse of model orthotopic breast cancer was suppressed by the combination treatment through the induction of ER stress and autophagy. These findings support the future evaluation of the novel HDACi TMU-35435, as a potent radiosensitizer in TNBC.
放射治疗(RT)是三阴性乳腺癌(TNBC)的主要治疗方法之一。然而,由于放疗的转移潜能和几种癌症的放射抗性,许多患者会出现放疗失败的情况。组蛋白去乙酰化酶抑制剂(HDACis)可作为放射增敏剂。在本研究中,我们调查了一种新型HDACi,TMU-35435,是否能通过诱导TNBC中错误折叠蛋白聚集和自噬来增强放射敏感性。与单独使用TMU-35435或照射(IR)治疗相比,联合治疗在TNBC细胞中显示出显著增强的毒性。联合治疗诱导了错误折叠蛋白聚集,并且TMU-35435抑制了HDAC6与动力蛋白的相互作用。此外,联合治疗诱导了内质网(ER)应激,但未引发细胞凋亡。另外,联合治疗导致自噬性细胞死亡。通过诱导ER应激和自噬,联合治疗抑制了原位乳腺癌小鼠模型中的肿瘤生长。这些发现支持未来对新型HDACi TMU-35435作为TNBC中一种有效的放射增敏剂进行评估。